Composite risk analysis: The composite risk assessment of recurrence risk enables clinicians to estimate the potential advantages of escalating adjuvant ET comprehensively and accurately for premenopausal women diagnosed with HR+/HER2- BC [15]. Here, ERBB2 is linked to breast cancer.